论文部分内容阅读
为探讨ＨＰＶ１６ 肿瘤相关抗原Ｅ６ 羧基端基因片段（Ｅ６Ｃ）在宫颈癌组织中的变异性以及采用Ｅ６Ｃ做为肿瘤治疗性疫苗抗原基因的可行性，采用ＰＣＲ方法自１８ 例单纯ＨＰＶ１６ ＤＮＡ 阳性的宫颈癌组织中扩增ＨＰＶ１６ Ｅ６ＣＤＮＡ，经单链构象多态性分析（ＳＳＣＰ）和ＤＮＡ序列测定法检测其基因变异性。ＳＳＣＰ分析结果显示，１８ 例宫颈癌组织中ＨＰＶ１６ Ｅ６ＣＤＮＡ 电泳条带与标准对照ＤＮＡ 条带一致，提示无基因变异现象存在，ＤＮＡ 序列测定也证实Ｅ６Ｃ编码区内无核苷酸突变。该研究证实采用ＨＰＶ１６ Ｅ６Ｃ端基因片段作为ＨＰＶ疫苗候选基因可行，为进一步研制ＨＰＶ１６ ＤＮＡ 疫苗奠定了基础
In order to investigate the variability of E6C in cervical cancer and the feasibility of using E6C as a therapeutic vaccine antigen, HPV16 DNA was isolated from 18 cases of HPV16 DNA positive cervical cancer The HPV16 E6 cDNA was amplified by PCR, and the genetic variation was detected by single strand conformation polymorphism (SSCP) and DNA sequencing. SSCP analysis showed that the bands of HPV16 E6 cDNA in 18 cervical cancer tissues were consistent with the standard control DNA bands, indicating that there was no gene mutation. DNA sequencing confirmed that there was no nucleotide mutation in the E6C coding region. This study confirmed that the use of HPV16 E6C gene fragment as HPV vaccine candidate gene is feasible and laid the foundation for further development of HPV16 DNA vaccine